对呼吸道病毒感染基于细胞的疗法的RT期刊论文SR电子T1当前状态：适用性COVID-19 JF欧洲呼吸杂志JO欧洲呼吸ĴFD欧洲呼吸协会SP 2000858 DO 10.1183 / 13993003.00858-2020 VO 55 6 A1 Khoury的，188bet官网地址Maroun A1 Cuenca, Jimena A1 Cruz, Fernanda F. A1 Figueroa, Fernando E. A1 Rocco, Patricia R.M. A1 Weiss, Daniel J. YR 2020 UL //www.qdcxjkg.com/content/55/6/2000858.abstract AB The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.It is imperative to better comprehend the rationale and underlying data that both support and refute effectiveness of MSCs in respiratory virus infections, and to define the targeted patient population and potential cell therapy approaches for COVID-19 https://bit.ly/2VbmYXs